Drugs / Shexiang Baoxin Pill
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07153744 | Sep 2025 → Dec 2028 expected | acute myocardial infarction | Shanghai Hutchison Pharmaceuticals Limited | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03072121 | Jun 2017 → Dec 2018 | coronary artery disorder | Jun Li | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shexiang Baoxin Pill | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07153744 ↗ |
| Known as | MUSKARDIA | “Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction” NCT07153744 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Shexiang Baoxin Pill (SBP), a type of Chinese patent medicine, has been widely used to treat CAD in China for many years.” PMID 29444778 ↗ Feb 2018 |
| Route | Oral | “Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months” NCT03072121 ↗ |